Introduction
============

Alzheimer\'s disease (AD) is the leading cause of age-related dementia ([Selkoe 1999](#Selkoe1999){ref-type="bib"}). Certain familial forms of AD (FAD) are characterized by an autosomal-dominant inheritance pattern and a tragically early age of onset, and most of these have been linked to mutations in the two presenilin genes (*PS1, PS2*). The *PS1* and *PS2* genes encode highly conserved, polytopic integral membrane proteins that are widely expressed not only within the central nervous system ([Cribbs et al. 1996](#Cribbsetal1996){ref-type="bib"}), but also in many peripheral tissues ([Sherrington et al. 1995](#Sherringtonetal1995){ref-type="bib"}). Intracellularly, in both neural and nonneuronal cells, the presenilins are localized predominantly to the ER ([Cook et al. 1996](#Cooketal1996){ref-type="bib"}).

The precise mechanisms by which presenilin mutations lead to AD neurodegeneration are currently unresolved. It is well established that presenilin mutations lead to increased production of the longer species of β-amyloid (Aβ) from the Aβ precursor protein (APP; [Scheuner et al. 1996](#Scheuneretal1996){ref-type="bib"}). APP mismetabolism, however, need not represent the exclusive or most primary consequence of presenilin mutations. It remains possible that other pathological effects of presenilin mutations upstream of and/or independent of Aβ generation may also contribute to the molecular and cellular changes characterizing AD neurodegeneration.

Mounting evidence has established that presenilin mutations confer highly specific alterations in intracellular calcium signaling pathways. For instance, a potentiation of inositol 1,4,5-trisphosphate (InsP~3~)-mediated calcium signals has been documented in an array of experimental systems expressing *PS1* mutations, ranging from *Xenopus* oocytes to transgenic animals ([Guo et al. 1996](#Guoetal1996){ref-type="bib"}, [Guo et al. 1998](#Guoetal1998){ref-type="bib"}, [Guo et al. 1999](#Guoetal1999){ref-type="bib"}; [Begley et al. 1999](#Begleyetal1999){ref-type="bib"}; [Leissring et al. 1999a](#Leissringetal1999a){ref-type="bib"},[Leissring et al. 1999b](#Leissringetal1999b){ref-type="bib"}). Similar alterations have also been observed in studies of human fibroblasts harboring FAD mutations ([Ito et al. 1994](#Itoetal1994){ref-type="bib"}; [Gibson et al. 1996](#Gibsonetal1996){ref-type="bib"}; [Etcheberrigaray et al. 1998](#Etcheberrigarayetal1998){ref-type="bib"}). The calcium signaling changes in FAD fibroblasts are highly selective and specific for the disease, being present in affected individuals, but not in unaffected family members ([Etcheberrigaray et al. 1998](#Etcheberrigarayetal1998){ref-type="bib"}). Moreover, mutations in *PS2* produce alterations in calcium signaling indistinguishable from *PS1* mutations ([Leissring et al. 1999a](#Leissringetal1999a){ref-type="bib"},[Leissring et al. 1999b](#Leissringetal1999b){ref-type="bib"}), providing further support that these changes represent a common pathogenic feature of all FAD-linked presenilin mutations.

Several lines of evidence suggest that the dysregulation of calcium signaling conferred by presenilin mutations plays a causal role in the pathogenesis of FAD, underlying both the neuronal degeneration and the hallmark pathological features of the disease. For instance, elevated levels of cytosolic calcium (\[Ca^2+^\]~i~) in cultured cells can modulate the processing of APP and thereby increase Aβ production ([Querfurth and Selkoe 1994](#QuerfurthandSelkoe1994){ref-type="bib"}). This underscores the likelihood that calcium dysregulation is at least one cause of increased Aβ production, and thus possibly contributes to plaque formation. Furthermore, increased \[Ca^2+^\]~i~ has also been shown to increase hyperphosphorylation of tau ([Mattson et al. 1991](#Mattsonetal1991){ref-type="bib"}). Finally, altered calcium homeostasis is centrally involved in the increased susceptibility to cell death conferred by *PS1* mutations ([Guo et al. 1996](#Guoetal1996){ref-type="bib"}, [Guo et al. 1998](#Guoetal1998){ref-type="bib"}, [Guo et al. 1999](#Guoetal1999){ref-type="bib"}; [Mattson et al. 2000](#Mattsonetal2000){ref-type="bib"}).

Despite the likely involvement of calcium disturbances in the pathogenesis of FAD, very little is known about the precise cellular mechanisms by which presenilin mutations alter calcium signaling pathways. To address this issue, we studied calcium signaling in fibroblasts from homozygous mutant *PS1* knockin (KI) mice. In these genetically altered mice, the endogenous mouse *PS1* gene has been replaced by the human counterpart containing the FAD-linked mutation, *PS1~M146V~* ([Guo et al. 1999](#Guoetal1999){ref-type="bib"}). This model possesses many advantages over other experimental paradigms, since the mutant human PS1 protein is expressed to physiological levels, and the endogenous tissue and cellular expression pattern is maintained. Hence, concerns about protein overexpression artifacts, ectopic expression, or confounding influences of the wild-type protein are obviated. Here, we demonstrate that agonist-evoked calcium signals are markedly potentiated in the *PS1~M146V~*-KI fibroblasts. In addition, we report the novel finding that *PS1~M146V~*-KI cells show deficits in capacitative calcium entry (CCE), i.e., the influx of extracellular calcium triggered by depletion of intracellular calcium stores. Finally, we provide evidence that both of these alterations are attributable to an abnormal elevation of ER calcium stores in the mutant cells. Thus, these findings provide a novel cellular mechanism to account for the calcium signaling alterations conferred by presenilin mutations, which could lead to the development of novel therapeutics for presenilin-associated FAD.

Materials and Methods
=====================

Cell Culture
------------

The derivation and characterization of the *PS1~M146V~*-KI mice has been described elsewhere ([Guo et al. 1999](#Guoetal1999){ref-type="bib"}). To isolate fibroblasts, snips of tail from neonatal homozygous *PS1~M146V~*-KI animals and controls were washed with 70% ethanol, minced in CMF (Ca^2+^- and Mg^2+^-free HBSS), and incubated for 30 min at 37°C in 2.5 ml of TCH solution (0.125% trypsin, 0.5 mM EDTA and 1 mg/ml collagenase Type V (Sigma Chemical Co.) in HBSS. After quenching the reaction by addition of DME supplemented with 20% FBS, the supernatant was removed and spun at 225 *g* for 5 min, and the pelleted cells were resuspended in DME/20% FBS. Cells were maintained at 37°C in a 5% CO~2~ atmosphere. For calcium imaging experiments, P1-P4 cultures were plated onto glass-bottomed 6-cm petri dishes (MatTek Corp.) and grown to near confluency. 1--2 h before imaging, cells were loaded for 45 min at room temperature with 5 μM Fura 2-AM supplemented with pluronic acid F-127 (Molecular Probes) in Hepes-buffered control solution (HCSS) containing 120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl~2~, 2 mM CaCl~2~, 15 mM glucose, 20 mM Hepes, pH 7.3, and 0.5% phenol red (calcium-deficient HCSS contained 1 mM EGTA and no CaCl~2~). Cells were washed three times with HCSS and allowed to incubate for at least 30 min before imaging. All reagents were purchased from Life Technologies, Inc. unless otherwise noted.

Calcium Imaging
---------------

Measurements of \[Ca^2+^\]~i~ were obtained using the InCyt *Im*2™ Ratio Imaging System (Intracellular Imaging Inc.) using excitation at 340 and 380 nm. The system was calibrated using stock solutions containing either no calcium (0 calcium plus 1 mM EGTA) or a saturating level of calcium (1 mM) using the formula \[Ca^2+^\]~i~ = *K* ~d~(225) \[(R−Rmin)/(Rmax−R)\] (Fo/Fs). Drugs were added by superfusion via a peristaltic pump and removed by vacuum. All experiments were performed using fibroblasts harvested from at least three different animals (*n* = 5--28 cells per experiment). Quantitative data were analyzed by one-way ANOVA and are expressed as mean ± SEM.

Results
=======

Potentiation of Agonist-evoked Calcium Signals in Mutant PS1 Knockin Cells
--------------------------------------------------------------------------

We studied calcium signals in fibroblasts isolated from neonatal mutant *PS1* KI mice and controls using the cytosolic calcium indicator Fura-2 AM. To activate the phosphoinositide/calcium signaling cascade, cells were stimulated with the cell surface receptor agonists, bradykinin (BK; [Fig. 1](#F1){ref-type="fig"}) or bombesin (data not shown). In control fibroblasts, BK stimulation evoked calcium signals with two characteristic phases: a transient rise in \[Ca^2+^\]~i~ lasting seconds, followed by a sustained phase of elevated \[Ca^2+^\]~i~ lasting several minutes ([Fig. 1](#F1){ref-type="fig"} a).

Calcium signals in *PS1~M146V~*-KI fibroblasts differed from controls in several salient respects. First, the rate of rise of the calcium signal was significantly increased ([Fig. 1](#F1){ref-type="fig"}, a and b, inset). Second, the peak of the transient phase was significantly potentiated ([Fig. 1](#F1){ref-type="fig"}, a and b). Finally, the sustained phase of elevated \[Ca^2+^\]~i~ present in control cells was virtually absent in the mutant fibroblasts ([Fig. 1](#F1){ref-type="fig"}, a and b).

Impaired Capacitative Calcium Entry in Mutant PS1 Knockin Cells
---------------------------------------------------------------

The sustained elevation of \[Ca^2+^\]~i~ in control cells resembles CCE, in which depletion of ER calcium stores triggers the influx of extracellular calcium through store-operated calcium channels (SOCCs; [Lewis 1999](#Lewis1999){ref-type="bib"}). To determine whether the sustained phase resulted from calcium influx, we stimulated cells with BK in calcium-deficient medium. Removal of extracellular calcium abolished the sustained phase in control cells, but had little effect on the calcium signal in *PS1~M146V~*-KI cells, indicating that the sustained phase of elevated \[Ca^2+^\]~i~ in control cells reflects calcium influx (compare [Fig. 1](#F1){ref-type="fig"}, a and c). Notably, the initial calcium transients in both control and *PS1~M146V~*-KI cells, which reflect calcium release from intracellular stores, were relatively unaffected by removal of extracellular calcium (compare [Fig. 1](#F1){ref-type="fig"}, a and c). Therefore, the potentiation of the initial calcium transient seen in *PS1~M146V~*-KI cells is attributable to increased release of calcium from intracellular stores rather than calcium influx.

To determine if the sustained calcium phase reflected CCE, we treated control cells with SKF-96365, an agent known to block CCE through SOCCs ([Merritt et al. 1990](#Merrittetal1990){ref-type="bib"}). As illustrated in [Fig. 1](#F1){ref-type="fig"} d, SKF-96365 treatment eliminated the sustained phase of \[Ca^2+^\]~i~ in control cells stimulated with BK in calcium-containing medium. Collectively, these data indicate that the sustained phase of elevated \[Ca^2+^\]~i~ in control cells is CCE, and that CCE is disrupted in cells harboring a mutation in *PS1*.

To quantify the magnitude of CCE after agonist stimulation, cells were initially stimulated with BK in calcium-deficient medium. Subsequently, after the initial calcium transients had returned to baseline, the calcium-deficient medium was replaced with medium containing 2 mM calcium ([Fig. 2](#F2){ref-type="fig"} a). Relative to controls, the magnitude of CCE upon calcium readdition was significantly reduced in *PS1~M146V~*-KI cells after stimulation with 50 nM BK ([Fig. 2](#F2){ref-type="fig"}, a and b). Intriguingly, in similar experiments using higher concentrations of BK (5 μM), the deficits in CCE in *PS1~M146V~*-KI cells, though still present, were significantly attenuated (see [Fig. 3](#F3){ref-type="fig"}). Furthermore, no differences in CCE were observed after complete depletion of calcium stores with thapsigargin (TG; [Fig. 2c](#F2){ref-type="fig"} and [Fig. d](#F2){ref-type="fig"}, and [Fig. 3](#F3){ref-type="fig"}). Thus, as illustrated in [Fig. 3](#F3){ref-type="fig"}, the magnitude of the deficits in CCE in *PS1~M146V~*-KI cells varied according to the degree and type of stimulation, with weak agonist stimulation eliciting the greatest deficits and complete store depletion eliciting no deficits whatsoever.

Elevated Calcium-Store Content in Mutant PS1 Knockin Mice
---------------------------------------------------------

The preceding results suggested that the *PS1~M146V~*-KI cells possess functional SOCCs, but are impaired in their ability to trigger CCE when weakly stimulated. Since the trigger for CCE is the depletion of intracellular calcium stores, we hypothesized that CCE is impaired in *PS1~M146V~*-KI cells because their ER calcium levels are abnormally elevated. On this view, weak agonist stimulation, which elicits only a transient release of ER calcium through rapidly inactivating InsP~3~ receptors ([Parekh et al. 1997](#Parekhetal1997){ref-type="bib"}), fails to deplete stores in the *PS1~M146V~*-KI cells to the threshold required for CCE activation (see [Fig. 5](#F5){ref-type="fig"}). To test this idea, the intracellular calcium stores of resting cells were released by treatment with TG or ionomycin in the nominal absence of extracellular calcium ([Fig. 4](#F4){ref-type="fig"}). The TG-releasable calcium pool was significantly larger in *PS1~M146V~*-KI relative to controls, as indicated by increases in both the peak value of TG-evoked calcium transients ([Fig. 4](#F4){ref-type="fig"}, a and b) and in their rate of rise (1.67 ± 0.12 nM s^−1^ versus 1.11 ± 0.11 nM s^−1^, respectively, *P* \< 0.01). Similar results were obtained when cells were treated with the calcium ionophore ionomycin in calcium-deficient medium ([Fig. 4c](#F4){ref-type="fig"} and [Fig. d](#F4){ref-type="fig"}). These data indicate that intracellular calcium stores, including the ER, are increased in cells from *PS1~M146V~*-KI mice. Collectively, our results suggest that the potentiation of calcium transients and absence of CCE observed in mutant *PS1~M146V~*-KI cells are attributable to increased ER calcium levels.

Discussion
==========

In this study we investigated calcium signaling in fibroblasts from KI mice harboring a *PS1* mutation linked to FAD. Relative to controls, cytosolic calcium signals from *PS1~M146V~*-KI fibroblasts exhibited a significant potentiation in calcium released by agonist activation of the phosphoinositide signaling pathway. In addition, KI cells exhibited deficits in CCE evoked by agonist stimulation, but not by complete depletion of ER calcium stores. We conclude that both of these alterations are attributable to the elevation of ER calcium content in *PS1~M146V~*-KI fibroblasts.

The agonist-evoked calcium signals in *PS1~M146V~*-KI fibroblasts are virtually indistinguishable from comparable experiments with human fibroblasts from FAD patients harboring *PS1* mutations (compare our [Fig. 1](#F1){ref-type="fig"} a to Figure 1 a in [Ito et al. 1994](#Itoetal1994){ref-type="bib"}). Thus, the *PS1~M146V~*-KI animals faithfully mimic the calcium signaling changes seen in presenilin-associated FAD. Importantly, since the mutant PS1 protein is expressed to physiological levels in these animals ([Guo et al. 1999](#Guoetal1999){ref-type="bib"}), none of the observed changes is attributable to protein overexpression.

It is notable that, unlike human FAD fibroblasts, the cells in this study were isolated from neonatal animals. This suggests that the changes in calcium signaling in FAD fibroblasts do not merely reflect secondary consequences of AD pathogenesis, such as the accumulation of mitochondrial mutations during the lifetime of the individual that have been shown to affect calcium signaling in cybrids transformed with mitochondria from nonfamilial AD patients ([Sheehan et al. 1997](#Sheehanetal1997){ref-type="bib"}). Rather, our findings support the hypothesis that altered calcium signaling is an early and chronic consequence of *PS1* mutations, one that may play a causal role in the pathogenesis of FAD.

Although the present study was focused on fibroblasts, the potentiation of calcium transients has been described in neuronal cells from these same animals ([Guo et al. 1999](#Guoetal1999){ref-type="bib"}; Leissring, M.A., Y. Akbari, and F.M. LaFerla, manuscript in preparation). This strongly suggests that the alterations in calcium signaling observed in peripheral cells from FAD patients may be directly involved in FAD neurodegeneration and memory loss ([Disterhoft et al. 1994](#Disterhoftetal1994){ref-type="bib"}; [Mattson et al. 2000](#Mattsonetal2000){ref-type="bib"}). This finding also supports the use of fibroblasts as a model to study the pathological alterations in calcium signaling associated with presenilin mutations.

Our results suggest that elevated ER calcium levels are a fundamental cellular defect underlying the alterations in calcium signaling conferred by presenilin mutations. As illustrated in [Fig. 5](#F5){ref-type="fig"}, we postulate that the higher levels of ER calcium in *PS1~M146V~*-KI cells would impair CCE by preventing agonist stimulation from depleting intracellular calcium stores beyond the threshold level required to activate CCE. Moreover, this model provides a satisfactory cellular mechanism to account for several observations made in other experimental systems. First, elevated ER calcium levels, by increasing the driving force on calcium across the ER, would be expected to increase the amplitude of calcium release transients, as has been documented in many systems ([Ito et al. 1994](#Itoetal1994){ref-type="bib"}; [Gibson et al. 1996](#Gibsonetal1996){ref-type="bib"}; [Guo et al. 1996](#Guoetal1996){ref-type="bib"}, [Guo et al. 1998](#Guoetal1998){ref-type="bib"}; [Etcheberrigaray et al. 1998](#Etcheberrigarayetal1998){ref-type="bib"}; [Leissring et al. 1999a](#Leissringetal1999a){ref-type="bib"},[Leissring et al. 1999b](#Leissringetal1999b){ref-type="bib"}). Second, an increased driving force on calcium would also increase the rate of ER calcium release (see [Fig. 1](#F1){ref-type="fig"} a) and would account for our observations in *Xenopus* oocytes that mutant PS1 increases both the rate of calcium efflux and the average quantal content of elementary calcium release events, the fundamental building blocks making up global calcium signals ([Mattson et al. 2000](#Mattsonetal2000){ref-type="bib"}; Leissring, M.A., F.M. LaFerla, N. Callamaras, and I. Parker, manuscript submitted for publication). Third, because ER calcium levels can modulate the activity of IP~3~ receptors ([Missiaen et al. 1992](#Missiaenetal1992){ref-type="bib"}), elevated calcium stores may also account for the increased sensitivity of cells expressing presenilin mutations to IP~3~ stimulation. Finally, an overfilling of calcium stores may also explain the interesting observation that long-term potentiation is altered in mutant *PS1* transgenic animals ([Parent et al. 1999](#Parentetal1999){ref-type="bib"}; [Mattson et al. 2000](#Mattsonetal2000){ref-type="bib"}), raising the specter that calcium dysregulation may underlie the memory impairments characterizing AD ([Disterhoft et al. 1994](#Disterhoftetal1994){ref-type="bib"}).

The mechanism by which *PS1* mutations elevate intracellular calcium stores is not yet known. Intriguingly, however, FAD fibroblasts harboring *PS1* mutations have elevated levels of acylphosphatase, an enzyme that modulates the activity of the ER calcium-ATPases responsible for loading the ER ([Liguri et al. 1996](#Ligurietal1996){ref-type="bib"}). Thus, overactivation of ER calcium pumps may underlie the overfilling of calcium stores. Future research into the molecular mechanisms by which presenilin mutations increase ER calcium levels could uncover novel targets for therapeutic intervention.
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![Agonist-evoked calcium signals are altered in *PS1~M146V~*-KI fibroblasts: evidence for impaired capacitative calcium entry. a, Typical traces showing calcium signals induced by 50 nM BK. b, Quantitative data from *n* = 11 experiments showing mean basal \[Ca^2+^\]~i~, peak BK-evoked \[Ca^2+^\]~i~, and \[Ca^2+^\]~i~ 5 min after agonist stimulation. Cytosolic calcium signals in control cells contain two phases: a transient rise in \[Ca^2+^\]~i~ followed by a sustained elevation of \[Ca^2+^\]~i~ lasting many minutes. Note the absence of the sustained phase in the *PS1~M146V~*-KI fibroblasts. The inset shows quantitative data for the rates of rise of the initial calcium transients. c, Representative calcium signals evoked by 50 nM BK in calcium-deficient medium. Note that control cells lack the sustained phase of elevated \[Ca^2+^\]~i~ seen when extracellular calcium is present, whereas *PS1~M146V~*-KI are relatively unchanged (see a). d, Typical BK-evoked calcium signals in control cells incubated in calcium-containing medium with or without SFK-96365 (10 μM). Note that SKF-96365 reduces the sustained elevation of \[Ca^2+^\]~i~ normally seen in control cells. \**P* \< 0.01.](JCB0003123.f1){#F1}

![Capacitative calcium entry is impaired in *PS1~M146V~*-KI fibroblasts after weak agonist stimulation, but not complete depletion of calcium stores. a, Representative calcium signals evoked by addition of 50 nM BK in calcium deficient medium, followed by the readdition of 2 mM extracellular calcium. b, Quantitative data from *n* = 7 experiments showing basal \[Ca^2+^\]~i~, peak BK-evoked \[Ca^2+^\]~i~, and peak \[Ca^2+^\]~i~ 30 s after readdition of extracellular calcium. The inset shows quantitative data for the rates of rise of the initial calcium transients. c, Representative calcium signals after the addition of 1 μM TG in calcium-deficient medium, followed by the readdition of 2 mM extracellular calcium. d, Quantitative data from *n* = 9 experiments showing basal \[Ca^2+^\]~i~, peak TG-evoked \[Ca^2+^\]~i~, and peak \[Ca^2+^\]~i~ after readdition of extracellular calcium. \**P* \< 0.01.](JCB0003123.f2){#F2}

![Comparison of capacitative calcium entry evoked by weak or strong agonist stimulation or TG treatment. Data are shown for experiments using the protocol illustrated in [Fig. 2](#F2){ref-type="fig"}, in which cells were stimulated with either 0.05 μM BK, 5 μM BK, or 1 μM TG. Note that the data are expressed as the increase in \[Ca^2+^\]~i~ relative to \[Ca^2+^\]~i~ 30 s before readdition of extracellular calcium. \**P* \< 0.01.](JCB0003123.f3){#F3}

![Intracellular calcium-store content is elevated in *PS1~M146V~*-KI fibroblasts. a, Typical calcium signals evoked by 1 μM TG in calcium-deficient medium. b, Quantitative data for *n* = 7 experiments showing basal \[Ca^2+^\]~i~ and peak \[Ca^2+^\]~i~ induced by TG treatment. c, Typical calcium signals evoked by 1 μM ionomycin (IONO) in calcium-deficient medium. d, Quantitative data for *n* = 9 experiments showing basal \[Ca^2+^\]~i~ and peak \[Ca^2+^\]~i~ evoked by ionomycin treatment. \**P* \< 0.01.](JCB0003123.f4){#F4}

![Model of the perturbations in calcium signaling in *PS1~M146V~*-KI mice. a, Schematic diagram illustrating changes in cytosolic calcium signals after weak agonist stimulation. b, Similar diagram showing calcium levels within the lumen of the ER. After weak agonist stimulation, luminal calcium levels in control cells fall well below the threshold level required for activation of CCE. In contrast, weak agonist stimulation barely triggers CCE in *PS1~M146V~*-KI fibroblasts because luminal calcium levels are abnormally elevated.](JCB0003123.f5){#F5}
